UK waitlist for Novo Nordisk’s Wegovy reaches 30,000 a week, tripling after approval

Novo Nordisk’s weight‑loss injection Wegovy has been approved in the United Kingdom. Within a week of the green light, a major online pharmacy reported that its waiting list surged to roughly 30,000 patients.

The rapid increase reflects strong demand from individuals seeking the GLP‑1 therapy, which has been popular in other markets for its efficacy in reducing body weight.

Analysts see the swelling queue as a positive signal for Novo Nordisk’s revenue outlook, suggesting that the drug could quickly become a significant contributor to the company’s sales in Europe.